Breaking News, Collaborations & Alliances

Promethera Biosciences Acquires Baliopharm

Promethera will now have control over Baliopharm’s entire antibody development programs

Promethera Biosciences has acquired Baliopharm AG.   The transaction adds to Promethera’s pipeline with an innovative antibody-based drug candidate that specifically binds to the tumor necrosis factor receptor 1 (TNF-R1). Combining this novel therapeutic strategy with Promethera’s unique liver cell-based therapies could provide improved treatment option for patients suffering from Nonalcoholic steatohepatitis (NASH) and potentially other severe liver diseases. Financial details of the tr...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters